Potential New Biomarkers in Lung Cancer

For High-Definition, Click

Earlier studies have suggested that patients with rich expression of EGFR might benefit from treatment with an EGFR-targeted monoclonal antibody, such as necitumumab. Researchers are currently exploring EGFR expression in tissues samples from patients enrolled in the phase III SQUIRE trial, which examined necitumumab in non-small cell lung cancer (NSCLC).

Additionally, there is interest in CDKN2A deletions as a potential predictor of response to CDK4/6 inhibitors. In a phase II study, treatment with palbociclib was well tolerated and demonstrated stable disease in 50% of evaluable patients in previously treated patients with CDKN2A inactivated NSCLC. These results warrant further investigation, believes Ramaswamy Govindan, MD.